Stock Region Penny Picks
Stock Region Penny Picks Watchlist Newsletter: Sunday, January 18, 2026
Stock Region Penny Picks Watchlist Newsletter: Sunday, January 18, 2026
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: The following content is for informational and educational purposes only. It is not financial advice. We are not financial advisors. All investment strategies and investments involve risk of loss. Nothing contained in this publication should be construed as investment advice. Any reference to an investment’s past or potential performance is not, and should not be construed as, a recommendation or as a guarantee of any specific outcome or profit.
It’s been a wild ride, and we’re seeing some serious movers and shakers out there. Let’s dive into the stocks that are lighting up our screens and could be worth watching.
$JAGX - Jaguar Health
JAGX absolutely exploded last week, running up over 100% to hit $1.58 on massive volume. This wasn’t just a random pump, either. The catalyst was a huge $38 million licensing deal with Future Pak for their Crofelemer products. This is the kind of news that fundamentally changes the game for a company. A deal of this size brings not only a significant cash infusion but also major validation for their product line. The question now is, can it hold these gains and build a new support level? After a run like that, some profit-taking is expected, but this move has firmly put JAGX back on the map.
$IBRX - ImmunityBio
In the biotech world, data is king, and ImmunityBio just delivered some royalty-worthy results. They announced a durable complete response of 15 months with their chemotherapy-free CAR-NK cell therapy in a lymphoma patient. Let’s break that down: “chemo-free” and “durable complete response” are two of the most beautiful phrases you can hear in oncology research. This is a massive step forward, suggesting their therapy has real, lasting power. Biotech can be a volatile sector, but positive clinical data like this is the lifeblood of progress and can often lead to sustained investor interest.
$PFSA - Profusa
We have a major milestone alert! Profusa has officially launched its Lumee™ Tissue Oxygen research offerings and, most importantly, is initiating its first commercial revenue. This is the moment every development-stage company works toward—the transition from burning cash to making it. It’s one thing to have a great idea; it’s another thing entirely to start selling it. This launch signals that the company is moving into its next phase of growth. We’ll be watching closely to see how the market adoption of Lumee™ progresses and what that revenue stream starts to look like.
$LCFY - Locafy
Partnerships are a powerful way to accelerate growth, and Locafy is making a smart move. They’ve expanded their partnership with Experience.com to push their Localizer product across the home services market. This is a fantastic strategy. Instead of building a sales force from the ground up, they are plugging into an existing network to drive sales. It’s efficient, scalable, and could significantly boost their market penetration in 2026. Keep an eye on how this collaboration develops.
$JFBR - Jeffs’ Brands
Here’s an interesting one in the tech and security space. A Jeffs’ Brands subsidiary, KeepZone AI, has locked in a distribution agreement with a developer of advanced vehicle and threat detection systems. This move puts Jeffs’ Brands in the middle of a very relevant and growing industry. Security and AI are hot sectors, and new distribution channels mean more potential customers and revenue. It’s a solid strategic move to expand their reach.
That’s a wrap for today’s watchlist. As always, do your own research, stay sharp, and let’s see what the market has in store for us.
Happy trading!
Disclaimer: We may hold positions in some of the stocks mentioned. Again, this is not financial advice. Please conduct your own due diligence before making any investment decisions.